当前位置: X-MOL 学术Clin. Transl. Immunol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
CD8+ tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous de novo metastatic colorectal carcinoma do not track with survival.
Clinical & Translational Immunology ( IF 4.6 ) Pub Date : 2020-07-17 , DOI: 10.1002/cti2.1155
Rosemary Millen 1, 2, 3 , Shona Hendry 4, 5 , Vignesh Narasimhan 1, 2 , Rebecca Abbott 1, 2 , Matthew Croxford 6 , Peter Gibbs 7, 8 , Jeanne Tie 1, 2, 6, 7, 8 , Hui-Li Wong 7, 8 , Ian Jones 7 , Suzanne Kosmider 6, 7 , David Byrne 1, 2 , John Zalcberg 9, 10 , Stephen Fox 1, 2 , Jayesh Desai 1, 2 , Kumar Visvanathan 3, 11 , Robert G Ramsay 1, 2 , Ben Tran 1, 2, 7, 8
Affiliation  

Tumor‐infiltrating lymphocytes (TIL), particularly CD8+ TILs in patients with colorectal cancer (CRC), are highly prognostic in the early‐disease stages (I‐II). In metastatic disease (stage IV; mCRC), their influence is less well defined. It has presumably failed to contain tumor cells to the primary site; however, is this evident? We explored the prognostic impact of TILs at the primary site in patients who presented de novo with mCRC.

中文翻译:

同步性新发转移性结直肠癌患者原发肿瘤内的 CD8+ 肿瘤浸润淋巴细胞不随生存而变化。

肿瘤浸润淋巴细胞 (TIL),特别是结直肠癌 (CRC) 患者中的CD8 + TIL,在疾病早期阶段具有高度预后作用 (I-II)。在转移性疾病(IV 期;mCRC)中,它们的影响尚不明确。它可能未能将肿瘤细胞限制在原发部位;然而,这明显吗?我们探讨了原发部位 TIL 对新发mCRC患者的预后影响。
更新日期:2020-07-18
down
wechat
bug